Is CNMD or HAE more profitable?

Haemonetics has a net margin of 7.12% compared to CONMED's net margin of 4.12%. Haemonetics' return on equity of 27.55% beat CONMED's return on equity. Company Net Margins Return on Equity Return on Assets CONMED 4.12% 14.31% 6.33% Haemonetics 7.12% 27.55% 9.65%

Does the media refer more to CNMD or HAE?

In the previous week, Haemonetics had 6 more articles in the media than CONMED. MarketBeat recorded 7 mentions for Haemonetics and 1 mentions for CONMED. CONMED's average media sentiment score of 0.45 beat Haemonetics' score of 0.33 indicating that CONMED is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment CONMED 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Haemonetics 1 Very Positive mention(s) 2 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has higher valuation & earnings, LIVN or CNMD?

CONMED has lower revenue, but higher earnings than LivaNova. LivaNova is trading at a lower price-to-earnings ratio than CONMED, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio LivaNova $1.39B 3.10 -$242.47M $3.38 23.08 CONMED $1.37B 0.99 $47.06M $1.85 24.55

Is LIVN or CNMD more profitable?

LivaNova has a net margin of 12.82% compared to CONMED's net margin of 4.12%. LivaNova's return on equity of 16.35% beat CONMED's return on equity. Company Net Margins Return on Equity Return on Assets LivaNova 12.82% 16.35% 7.76% CONMED 4.12% 14.31% 6.33%

Does the media favor LIVN or CNMD?

In the previous week, LivaNova had 6 more articles in the media than CONMED. MarketBeat recorded 7 mentions for LivaNova and 1 mentions for CONMED. CONMED's average media sentiment score of 0.45 beat LivaNova's score of 0.38 indicating that CONMED is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment LivaNova 3 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral CONMED 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has preferable valuation & earnings, CNMD or ITGR?

Integer has higher revenue and earnings than CONMED. CONMED is trading at a lower price-to-earnings ratio than Integer, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio CONMED $1.37B 0.99 $47.06M $1.85 24.55 Integer $1.85B 2.32 $102.81M $3.66 34.52

Is CNMD or ITGR more profitable?

Integer has a net margin of 6.97% compared to CONMED's net margin of 4.12%. CONMED's return on equity of 14.31% beat Integer's return on equity. Company Net Margins Return on Equity Return on Assets CONMED 4.12% 14.31% 6.33% Integer 6.97% 12.79% 6.48%

Does the media favor CNMD or ITGR?

In the previous week, Integer had 10 more articles in the media than CONMED. MarketBeat recorded 11 mentions for Integer and 1 mentions for CONMED. Integer's average media sentiment score of 0.59 beat CONMED's score of 0.45 indicating that Integer is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment CONMED 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Integer 5 Very Positive mention(s) 2 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Is CNMD or PLSE more profitable?

CONMED has a net margin of 4.12% compared to Pulse Biosciences' net margin of -6,755.78%. CONMED's return on equity of 14.31% beat Pulse Biosciences' return on equity. Company Net Margins Return on Equity Return on Assets CONMED 4.12% 14.31% 6.33% Pulse Biosciences -6,755.78% -94.42% -79.96%

Does the media refer more to CNMD or PLSE?

In the previous week, Pulse Biosciences had 5 more articles in the media than CONMED. MarketBeat recorded 6 mentions for Pulse Biosciences and 1 mentions for CONMED. CONMED's average media sentiment score of 0.45 beat Pulse Biosciences' score of 0.33 indicating that CONMED is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment CONMED 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Pulse Biosciences 1 Very Positive mention(s) 2 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

CONMED (CNMD) Competitors

$45.42 -0.71 (-1.54%)

Closing price 09/18/2026 03:59 PM Eastern

Extended Trading

$45.46 +0.04 (+0.09%)

As of 09/18/2026 07:30 PM Eastern

Compare

CNMD vs. MMSI, HAE, LIVN, ITGR, and PLSE

Should you buy CONMED stock or one of its competitors? CONMED's main competitors and comparable companies include Merit Medical Systems (MMSI), Haemonetics (HAE), LivaNova (LIVN), Integer (ITGR), and Pulse Biosciences (PLSE). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "healthcare equipment & supplies" industry.

How does CONMED compare to Merit Medical Systems?

Merit Medical Systems (NASDAQ:MMSI) and CONMED (NYSE:CNMD) are both healthcare companies, but which is the better stock? We will contrast the two companies based on the strength of their analyst recommendations, profitability, media sentiment, institutional ownership, risk, dividends, valuation and earnings.

Merit Medical Systems has a net margin of 9.22% compared to CONMED's net margin of 4.12%. CONMED's return on equity of 14.31% beat Merit Medical Systems' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Merit Medical Systems	9.22%	13.75%	8.10%
CONMED	4.12%	14.31%	6.33%

Merit Medical Systems has a beta of 0.49, indicating that its stock price is 51% less volatile than the broader market. Comparatively, CONMED has a beta of 0.9, indicating that its stock price is 10% less volatile than the broader market.

99.7% of Merit Medical Systems shares are owned by institutional investors. 0.7% of Merit Medical Systems shares are owned by insiders. Comparatively, 0.3% of CONMED shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

In the previous week, CONMED had 1 more articles in the media than Merit Medical Systems. MarketBeat recorded 1 mentions for CONMED and 0 mentions for Merit Medical Systems. Merit Medical Systems' average media sentiment score of 1.85 beat CONMED's score of 0.45 indicating that Merit Medical Systems is being referred to more favorably in the media.

Company	Overall Sentiment
Merit Medical Systems	Very Positive
CONMED	Neutral

Merit Medical Systems currently has a consensus target price of $100.00, suggesting a potential upside of 17.14%. CONMED has a consensus target price of $41.40, suggesting a potential downside of 8.85%. Given Merit Medical Systems' stronger consensus rating and higher probable upside, analysts plainly believe Merit Medical Systems is more favorable than CONMED.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Merit Medical Systems	0 Sell rating(s)	3 Hold rating(s)	8 Buy rating(s)	1 Strong Buy rating(s)	2.83
CONMED	1 Sell rating(s)	7 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.88

Merit Medical Systems has higher revenue and earnings than CONMED. CONMED is trading at a lower price-to-earnings ratio than Merit Medical Systems, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Merit Medical Systems	$1.52B	3.36	$128.49M	$2.42	35.28
CONMED	$1.37B	0.99	$47.06M	$1.85	24.55

Summary

Merit Medical Systems beats CONMED on 14 of the 17 factors compared between the two stocks.

How does CONMED compare to Haemonetics?

CONMED (NYSE:CNMD) and Haemonetics (NYSE:HAE) are both healthcare companies, but which is the superior investment? We will compare the two businesses based on the strength of their media sentiment, valuation, earnings, profitability, dividends, risk, analyst recommendations and institutional ownership.

99.7% of Haemonetics shares are held by institutional investors. 0.3% of CONMED shares are held by insiders. Comparatively, 2.1% of Haemonetics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Haemonetics has lower revenue, but higher earnings than CONMED. CONMED is trading at a lower price-to-earnings ratio than Haemonetics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
CONMED	$1.37B	0.99	$47.06M	$1.85	24.55
Haemonetics	$1.33B	3.70	$97.31M	$2.04	53.17

CONMED presently has a consensus target price of $41.40, indicating a potential downside of 8.85%. Haemonetics has a consensus target price of $99.78, indicating a potential downside of 8.00%. Given Haemonetics' stronger consensus rating and higher probable upside, analysts plainly believe Haemonetics is more favorable than CONMED.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
CONMED	1 Sell rating(s)	7 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.88
Haemonetics	0 Sell rating(s)	4 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.73

Haemonetics has a net margin of 7.12% compared to CONMED's net margin of 4.12%. Haemonetics' return on equity of 27.55% beat CONMED's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
CONMED	4.12%	14.31%	6.33%
Haemonetics	7.12%	27.55%	9.65%

CONMED has a beta of 0.9, meaning that its stock price is 10% less volatile than the broader market. Comparatively, Haemonetics has a beta of 0.54, meaning that its stock price is 46% less volatile than the broader market.

In the previous week, Haemonetics had 6 more articles in the media than CONMED. MarketBeat recorded 7 mentions for Haemonetics and 1 mentions for CONMED. CONMED's average media sentiment score of 0.45 beat Haemonetics' score of 0.33 indicating that CONMED is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
CONMED	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Haemonetics	1 Very Positive mention(s)	2 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

Haemonetics beats CONMED on 14 of the 17 factors compared between the two stocks.

How does CONMED compare to LivaNova?

LivaNova (NASDAQ:LIVN) and CONMED (NYSE:CNMD) are both healthcare companies, but which is the better stock? We will contrast the two companies based on the strength of their media sentiment, risk, dividends, valuation, institutional ownership, profitability, earnings and analyst recommendations.

CONMED has lower revenue, but higher earnings than LivaNova. LivaNova is trading at a lower price-to-earnings ratio than CONMED, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
LivaNova	$1.39B	3.10	-$242.47M	$3.38	23.08
CONMED	$1.37B	0.99	$47.06M	$1.85	24.55

97.6% of LivaNova shares are owned by institutional investors. 0.4% of LivaNova shares are owned by company insiders. Comparatively, 0.3% of CONMED shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

LivaNova presently has a consensus price target of $84.13, indicating a potential upside of 7.84%. CONMED has a consensus price target of $41.40, indicating a potential downside of 8.85%. Given LivaNova's stronger consensus rating and higher probable upside, equities analysts plainly believe LivaNova is more favorable than CONMED.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
LivaNova	0 Sell rating(s)	5 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.55
CONMED	1 Sell rating(s)	7 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.88

In the previous week, LivaNova had 6 more articles in the media than CONMED. MarketBeat recorded 7 mentions for LivaNova and 1 mentions for CONMED. CONMED's average media sentiment score of 0.45 beat LivaNova's score of 0.38 indicating that CONMED is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
LivaNova	3 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
CONMED	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

LivaNova has a net margin of 12.82% compared to CONMED's net margin of 4.12%. LivaNova's return on equity of 16.35% beat CONMED's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
LivaNova	12.82%	16.35%	7.76%
CONMED	4.12%	14.31%	6.33%

LivaNova has a beta of 0.87, suggesting that its stock price is 13% less volatile than the broader market. Comparatively, CONMED has a beta of 0.9, suggesting that its stock price is 10% less volatile than the broader market.

Summary

LivaNova beats CONMED on 12 of the 16 factors compared between the two stocks.

How does CONMED compare to Integer?

CONMED (NYSE:CNMD) and Integer (NYSE:ITGR) are both healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their analyst recommendations, media sentiment, earnings, dividends, valuation, institutional ownership, profitability and risk.

CONMED currently has a consensus price target of $41.40, suggesting a potential downside of 8.85%. Integer has a consensus price target of $109.86, suggesting a potential downside of 13.05%. Given CONMED's higher probable upside, equities research analysts plainly believe CONMED is more favorable than Integer.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
CONMED	1 Sell rating(s)	7 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.88
Integer	0 Sell rating(s)	13 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.07

In the previous week, Integer had 10 more articles in the media than CONMED. MarketBeat recorded 11 mentions for Integer and 1 mentions for CONMED. Integer's average media sentiment score of 0.59 beat CONMED's score of 0.45 indicating that Integer is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
CONMED	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Integer	5 Very Positive mention(s)	2 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

99.3% of Integer shares are held by institutional investors. 0.3% of CONMED shares are held by insiders. Comparatively, 1.1% of Integer shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

CONMED has a beta of 0.9, suggesting that its share price is 10% less volatile than the broader market. Comparatively, Integer has a beta of 0.62, suggesting that its share price is 38% less volatile than the broader market.

Integer has a net margin of 6.97% compared to CONMED's net margin of 4.12%. CONMED's return on equity of 14.31% beat Integer's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
CONMED	4.12%	14.31%	6.33%
Integer	6.97%	12.79%	6.48%

Integer has higher revenue and earnings than CONMED. CONMED is trading at a lower price-to-earnings ratio than Integer, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
CONMED	$1.37B	0.99	$47.06M	$1.85	24.55
Integer	$1.85B	2.32	$102.81M	$3.66	34.52

Summary

Integer beats CONMED on 13 of the 16 factors compared between the two stocks.

How does CONMED compare to Pulse Biosciences?

CONMED (NYSE:CNMD) and Pulse Biosciences (NASDAQ:PLSE) are both healthcare companies, but which is the superior stock? We will contrast the two businesses based on the strength of their institutional ownership, risk, valuation, dividends, analyst recommendations, profitability, media sentiment and earnings.

CONMED has a beta of 0.9, suggesting that its share price is 10% less volatile than the broader market. Comparatively, Pulse Biosciences has a beta of 1.63, suggesting that its share price is 63% more volatile than the broader market.

In the previous week, Pulse Biosciences had 5 more articles in the media than CONMED. MarketBeat recorded 6 mentions for Pulse Biosciences and 1 mentions for CONMED. CONMED's average media sentiment score of 0.45 beat Pulse Biosciences' score of 0.33 indicating that CONMED is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
CONMED	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Pulse Biosciences	1 Very Positive mention(s)	2 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

CONMED has higher revenue and earnings than Pulse Biosciences. Pulse Biosciences is trading at a lower price-to-earnings ratio than CONMED, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
CONMED	$1.37B	0.99	$47.06M	$1.85	24.55
Pulse Biosciences	$350K	10,897.13	-$72.78M	-$1.18	N/A

CONMED has a net margin of 4.12% compared to Pulse Biosciences' net margin of -6,755.78%. CONMED's return on equity of 14.31% beat Pulse Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
CONMED	4.12%	14.31%	6.33%
Pulse Biosciences	-6,755.78%	-94.42%	-79.96%

77.0% of Pulse Biosciences shares are held by institutional investors. 0.3% of CONMED shares are held by company insiders. Comparatively, 74.0% of Pulse Biosciences shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

CONMED presently has a consensus target price of $41.40, indicating a potential downside of 8.85%. Pulse Biosciences has a consensus target price of $45.25, indicating a potential downside of 16.00%. Given CONMED's higher probable upside, analysts clearly believe CONMED is more favorable than Pulse Biosciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
CONMED	1 Sell rating(s)	7 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.88
Pulse Biosciences	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.83

Summary

CONMED beats Pulse Biosciences on 9 of the 17 factors compared between the two stocks.

Get CONMED News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding CNMD and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

CNMD vs. The Competition

Export

Metric	CONMED	Healthcare Equipment & Supplies Industry	Healthcare Sector	NYSE Exchange
Market Cap	$1.36B	$5.55B	$7.24B	$23.10B
Dividend Yield	N/A	1.80%	2.57%	3.62%
P/E Ratio	24.55	25.34	274.93	28.19
Price / Sales	0.99	72.49	646.01	20.34
Price / Cash	6.31	32.64	76.25	36.36
Price / Book	1.36	5.69	10.46	4.67
Net Income	$47.06M	$151.55M	$3.49B	$1.07B
7 Day Performance	-1.58%	0.66%	0.59%	-1.64%
1 Month Performance	-11.25%	-3.33%	-1.74%	-3.60%
1 Year Performance	-9.21%	6.79%	18.13%	8.41%

CONMED Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
CNMD CONMED	1.5064 of 5 stars	$45.42 -1.5%	$41.40 -8.9%	-9.2%	$1.36B	$1.37B	24.55	3,900	Analyst Upgrade High Trading Volume
MMSI Merit Medical Systems	3.4763 of 5 stars	$86.19 -0.9%	$100.00 +16.0%	+2.2%	$5.13B	$1.52B	35.49	7,500	Positive News
HAE Haemonetics	1.9303 of 5 stars	$106.17 -0.1%	$99.78 -6.0%	+114.6%	$4.79B	$1.35B	51.59	3,009	News Coverage
LIVN LivaNova	2.6493 of 5 stars	$79.82 -1.0%	$84.13 +5.4%	+41.8%	$4.39B	$1.39B	23.59	3,300
ITGR Integer	2.801 of 5 stars	$126.20 +0.1%	$109.86 -12.9%	+22.4%	$4.29B	$1.85B	34.47	11,000	Insider Trade

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NYSE:CNMD) was last updated on 9/20/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

CONMED (CNMD) Competitors

CNMD vs. MMSI, HAE, LIVN, ITGR, and PLSE

How does CONMED compare to Merit Medical Systems?

Summary

How does CONMED compare to Haemonetics?

Summary

How does CONMED compare to LivaNova?

Summary

How does CONMED compare to Integer?

Summary

How does CONMED compare to Pulse Biosciences?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CNMD vs. The Competition

CONMED Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

CONMED (CNMD) Competitors

CNMD vs. MMSI, HAE, LIVN, ITGR, and PLSE

How does CONMED compare to Merit Medical Systems?

Is MMSI or CNMD more profitable?

Which has more risk & volatility, MMSI or CNMD?

Do insiders & institutionals hold more shares of MMSI or CNMD?

Does the media favor MMSI or CNMD?

Do analysts prefer MMSI or CNMD?

Which has stronger valuation and earnings, MMSI or CNMD?

Summary

How does CONMED compare to Haemonetics?

Do institutionals & insiders have more ownership in CNMD or HAE?

Which has higher valuation & earnings, CNMD or HAE?

Do analysts recommend CNMD or HAE?

Is CNMD or HAE more profitable?

Which has more risk & volatility, CNMD or HAE?

Does the media refer more to CNMD or HAE?

Summary

How does CONMED compare to LivaNova?

Which has higher valuation & earnings, LIVN or CNMD?

Do insiders & institutionals believe in LIVN or CNMD?

Do analysts recommend LIVN or CNMD?

Does the media favor LIVN or CNMD?

Is LIVN or CNMD more profitable?

Which has more risk and volatility, LIVN or CNMD?

Summary

How does CONMED compare to Integer?

Do analysts prefer CNMD or ITGR?

Does the media favor CNMD or ITGR?

Do institutionals & insiders hold more shares of CNMD or ITGR?

Which has more risk & volatility, CNMD or ITGR?

Is CNMD or ITGR more profitable?

Which has preferable valuation & earnings, CNMD or ITGR?

Summary

How does CONMED compare to Pulse Biosciences?

Which has more risk & volatility, CNMD or PLSE?

Does the media refer more to CNMD or PLSE?

Which has higher valuation and earnings, CNMD or PLSE?

Is CNMD or PLSE more profitable?

Do institutionals and insiders have more ownership in CNMD or PLSE?

Do analysts rate CNMD or PLSE?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CNMD vs. The Competition

CONMED Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools